PR Newswire03.08.19
SynCardia Systems, LLC, manufacturer of the world's only clinically-proven and commercially approved total artificial heart, is pleased to announce that Don Webber has been named CEO.
Webber joined SynCardia in 2018 as COO, leading manufacturing operations and engineering, quality and supply chain logistics for the SynCardia product line, which includes the 70cc temporary Total Artificial Heart (TAH); the smaller 50cc TAH* designed to fit more women and adolescents; the Companion 2 Hospital Driver; and the Freedom Portable Driver, which allows stable TAH patients to be discharged from the hospital.
Webber's demonstrated leadership as COO led to his promotion in January 2019 to the chief executive office. To the position, he brings extensive management experience from more than 25 years in public and private sector life science companies. Prior to joining SynCardia, Webber had been the COO at OptiScan since 2010. In addition, he's previously served as VP of manufacturing operations at C.R. Bard, VP of operations at EKOS Corporation, and president and CEO of Mitralign. He holds a bachelor's degree in industrial engineering technology from the State University of New York and an MBA from Nova Southeastern University.
*The 50cc TAH is approved for use in Europe and Canada and undergoing an Investigational Device Exemption (IDE) clinical trial in the U.S.
Webber joined SynCardia in 2018 as COO, leading manufacturing operations and engineering, quality and supply chain logistics for the SynCardia product line, which includes the 70cc temporary Total Artificial Heart (TAH); the smaller 50cc TAH* designed to fit more women and adolescents; the Companion 2 Hospital Driver; and the Freedom Portable Driver, which allows stable TAH patients to be discharged from the hospital.
Webber's demonstrated leadership as COO led to his promotion in January 2019 to the chief executive office. To the position, he brings extensive management experience from more than 25 years in public and private sector life science companies. Prior to joining SynCardia, Webber had been the COO at OptiScan since 2010. In addition, he's previously served as VP of manufacturing operations at C.R. Bard, VP of operations at EKOS Corporation, and president and CEO of Mitralign. He holds a bachelor's degree in industrial engineering technology from the State University of New York and an MBA from Nova Southeastern University.
*The 50cc TAH is approved for use in Europe and Canada and undergoing an Investigational Device Exemption (IDE) clinical trial in the U.S.